BIOMARKER:

EGFR exon 19 deletion

News alerts, weekly reports and conference planners

Entrez ID:

1956

Related biomarkers:

‹

›

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : A1 ESMO 2022 - 3wk	afatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks afatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) osimertinib Sensitive : A1 ESMO 2022 - 3wk	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks osimertinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 3 weeks (New C3) gefitinib Sensitive : A1 J Cancer Res Clin Oncol - 3wk	gefitinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 3 weeks gefitinib Sensitive : A1 J Cancer Res Clin Oncol - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 Sensitive : C3 ESMO 2022 - 3wk	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1
EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	icotinib Sensitive: B - Late Trials icotinib Sensitive : B	icotinib Sensitive: B - Late Trials icotinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B	gefitinib + rivoceranib Sensitive: B - Late Trials gefitinib + rivoceranib Sensitive : B
EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B
EGFR exon 19 deletion	Lung Non-Small Cell Squamous Cancer	EGFR exon 19 deletion	Lung Non-Small Cell Squamous Cancer	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B	aumolertinib Sensitive: B - Late Trials aumolertinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B	furmonertinib Sensitive: B - Late Trials furmonertinib Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR exon 19 deletion	Small Cell Lung Cancer	EGFR exon 19 deletion	Small Cell Lung Cancer	gefitinib Sensitive: C1 - Off-label gefitinib Sensitive : C1	gefitinib Sensitive: C1 - Off-label gefitinib Sensitive : C1
EGFR exon 19 deletion	Lung Cancer	EGFR exon 19 deletion	Lung Cancer	gefitinib Sensitive: C1 - Off-label gefitinib Sensitive : C1	gefitinib Sensitive: C1 - Off-label gefitinib Sensitive : C1
EGFR exon 19 deletion	Small Cell Lung Cancer	EGFR exon 19 deletion	Small Cell Lung Cancer	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria osimertinib + gefitinib Sensitive : C2	osimertinib + gefitinib Sensitive: C2 – Inclusion Criteria osimertinib + gefitinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2	anlotinib + icotinib Sensitive: C2 – Inclusion Criteria anlotinib + icotinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: C2 – Inclusion Criteria amivantamab-vmjw + lazertinib Sensitive : C2	amivantamab-vmjw + lazertinib Sensitive: C2 – Inclusion Criteria amivantamab-vmjw + lazertinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2	bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria bevacizumab + osimertinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	tislelizumab Sensitive: C2 – Inclusion Criteria tislelizumab Sensitive : C2	tislelizumab Sensitive: C2 – Inclusion Criteria tislelizumab Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	lazertinib Sensitive: C2 – Inclusion Criteria lazertinib Sensitive : C2	lazertinib Sensitive: C2 – Inclusion Criteria lazertinib Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	BBT-176 Sensitive: C2 – Inclusion Criteria BBT-176 Sensitive : C2	BBT-176 Sensitive: C2 – Inclusion Criteria BBT-176 Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib + anlotinib Sensitive: C3 – Early Trials erlotinib + anlotinib Sensitive : C3	erlotinib + anlotinib Sensitive: C3 – Early Trials erlotinib + anlotinib Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	rivoceranib + camrelizumab Resistant: C3 – Early Trials rivoceranib + camrelizumab Resistant : C3	rivoceranib + camrelizumab Resistant: C3 – Early Trials rivoceranib + camrelizumab Resistant : C3

EGFR exon 19 deletion

Associations